Home / Health / New Antibiotic Choice Saves Golden Staph Patients
New Antibiotic Choice Saves Golden Staph Patients
18 Jun
Summary
- New research suggests alternative antibiotics are safer than flucloxacillin.
- Alternative antibiotics showed lower mortality rates in clinical trials.
- One alternative antibiotic significantly reduced kidney damage risk.
Treatment for golden staph infections is poised for a major change based on groundbreaking international research. A long-standing frontline antibiotic, flucloxacillin, has been found to carry a higher risk of severe side effects and a lower survival rate for patients. This revelation stems from a world-first clinical trial involving over 150 hospitals across 14 countries.
The comprehensive study tracked patients with golden staph bloodstream infections, comparing flucloxacillin against two alternative antibiotics: cefazolin and benzylpenicillin. The results, published in The Lancet and the New England Journal of Medicine, indicate that both alternatives are as effective at curing the infection.
Crucially, the alternative antibiotics demonstrated superior safety profiles. Cefazolin use was associated with a reduced risk of acute kidney damage and a better chance of survival compared to flucloxacillin. Benzylpenicillin even further improved survival rates for patients over the 90-day monitoring period, suggesting a significant advancement in patient care for this potentially deadly bacteria.
